

CLAIMS

- 1.- Use of the 2,5-dihydroxybenzenesulfonic acid or of any of its pharmaceutically acceptable salts for manufacturing of medicines applicable to the treatment of angiodependent diseases.
5
- 2.- Use according to claim 1 in which the angiodependent disease also presents a reduction of apoptosis.
- 3.- Use according to any of claims 1 or 2 in which the manufactured medicine is for application in the treatment of cancer.
10
- 4.- Use according to claim 3 characterized because the manufactured medicine is used to increase the antiproliferative effect of the cytostatic medicines in the treatment of cancer.
- 5.- Use according to any of claims 1 to 4 characterized because the salt preferred for the manufacturing of the medicine is the potassium salt of the 2,5-dihydroxybenzene sulfonic acid.
15
- 6.- Use according to any of the claims 1 to 4 characterized because the salt preferred for producing the medicine is the calcium salt of the 2,5-dihydroxybenzene sulfonic acid.
- 7.- Use according to any of the above claims 1 to 6 in which the manufactured medicine also includes an adequate amount of at least one pharmaceutically acceptable excipient.
20
- 8.- Use according to claim 1 in which the manufactured medicine is for application in the treatment of psoriasis.
- 9.- Use according to claim 8 characterized because the salt preferred for production of the medicine is the potassium salt of the 2,5-dihydroxybenzenesulfonic acid.
25

10. Use according to claim 8, characterized because the salt preferred for manufacturing of the medicine is the calcium salt of the 2,5-dihydroxybenzenesulfonic acid.
11. Use according to any of the above claims 8 to 10 in which the manufactured medicine also includes adequate amount of at least one pharmaceutically acceptable excipient.
- 5 12.- Use according to any of the claims 8 to 11 characterized because the medicine consists on a topical application formulation.
- 13.- Use according to claim 12 characterized because the medicine is a cream or unguent whose composition includes:
- 10 • A pharmaceutically efficient amount of the 2,5-dihydroxybenzenesulfonic acid or of any of its pharmaceutically acceptable salts.
 - A pharmaceutically acceptable amount of at least one alcohol.
 - A pharmaceutically acceptable amount of at least one emulsifier.
 - A pharmaceutically acceptable amount of at least one excipient.
 - 15 • A pharmaceutically acceptable amount of at least one excipient comprising a lipid phase, particularly vaseline
 - Distilled water
- 14.- Use according to claim 13 characterized because the medicine is a cream or unguent that presents a composition that includes:
- 20 • 5% of the potassium salt of the 2,5-dihydroxybenzenesulfonic acid
 - 2,5% of cetylic alcohol
 - 2,5% of stearic alcohol
 - 30% of liquid vaseline

- 30% of white soft paraffin
- 5% span (sorbitan oleate)
- q.s 100 g of distilled water